Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Crescita TherapeuticsTSX:CTX 20 3-1 Month Momentum % is 65.22% as of Aug. 17, 2026. GuruFocus rates TSX:CTX with a GF Score™ of 20/100. The stock has 5 warning signs investors should review. Among 1,025 Drug Manufacturers companies, Crescita Therapeutics ranks better than 98.15% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-17), Crescita Therapeutics's 3-1 Month Momentum % is 65.22%.
The industry rank for Crescita Therapeutics's 3-1 Month Momentum % or its related term are showing as below:
TSX:CTX's 3-1 Month Momentum % is ranked better than 98.15% of 1025
companies
in the Drug Manufacturers industry
Industry Median: -5.65
vs TSX:CTX: 65.22
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Crescita Therapeutics 3-1 Month Momentum % Related Terms
TSX:CTX vs ZTS: 3-1 Month Momentum % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Crescita Therapeutics's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Crescita Therapeutics 3-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Crescita Therapeutics's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Crescita Therapeutics's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Crescita Therapeutics (TSX:CTX) has a 3-1 Month Momentum % of 65.22% as of Aug. 17, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Crescita Therapeutics and its competitors. According to the industry distribution chart, Crescita Therapeutics ranks #19 out of 1025 companies in the Drug Manufacturers industry, placing it in the top 1.9%.
Is Crescita Therapeutics' 3-1 Month Momentum % too high?
Crescita Therapeutics' current 3-1 Month Momentum % is 65.22%. Based on the distribution chart, Crescita Therapeutics ranks #19 out of 1025 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Crescita Therapeutics has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Crescita Therapeutics' 3-1 Month Momentum % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Crescita Therapeutics ranks #19 out of 1025 companies for 3-1 Month Momentum %. This places Crescita Therapeutics in the top 2% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Drug Manufacturers company?
A good 3-1 Month Momentum % depends on the Drug Manufacturers industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Crescita Therapeutics and its competitors. Crescita Therapeutics's current 3-1 Month Momentum % is 65.22%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crescita Therapeutics stock overvalued right now?
Crescita Therapeutics (TSX:CTX) has a current 3-1 Month Momentum % of 65.22%. The current 3-1 Month Momentum % is 65.22%. Crescita Therapeutics' overall GF Score™ is 20/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Crescita Therapeutics (TSX:CTX), the current 3-1 Month Momentum % is 65.22% as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Crescita Therapeutics Inc is a commercial dermatology company with in-house research & development and manufacturing capabilities. The company offers a portfolio of non-prescription skincare products and early to commercial-stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin. The company has three reportable segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The firm generates its revenue from Commercial Skincare Product Sales in Canada followed by USA and Rest of the world.
20GF Score
Get the complete analysis for TSX:CTX
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:CTX has been successfully added to your 
